We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
[Preclinical pharmacological study of a novel myocardial perfusion agent: 99mTc-Q3].
In order to provide an experimental foundation for clinical study, we made a preclinical pharmacological investigation of 99mTc-Q3, a novel myocardial perfusion imaging agent, technetium-99m-N,N'-ethylenebis (acetylace-toneiminato) bis (tris (3-methoxy-1-proply) phosphine). After the preparation of this compound, the kinetics of blood clearance in rabbits, biodistribution in mice, measurement of plasma protein binding rate, and myocardial perfusion imaging in dog were carried out. The labelling efficiency and radiochemical purity measured were over 99%, and the stability (in vitro) was good and stable up to 6 hr of testing at room temperature. The pharmacokinetics met the two-compartment model with 0.23 +/- 0.09 ml/min of excellent blood clearance, an initial half-time of 1.5979 +/- 0.4182 min, and a late half-time of 203 +/- 25.83 min. The biodistribution as shown in myocardial accumulation was earlier, the radioactive value was higher, and once extracted, it remained relatively constant in the myocardium for at least 4 hr. The tracer was rapidly cleared from the blood, lung and the liver. The scintigraphy imaging in dog demonstrated that it was rapidly cleared from the lung, and the radioactive concentration approached that of background 1 hr after injection. At 15 min after injection, the myocardial imaging displayed clearly up to 3 hr. In vitro protein binding rate was low (7.13 +/- 0.42%). The tolerance of this drug in mice was 500 times as much as in humans. In conclusion, 99mTc-Q3 exhibits favorable stability, biological property and safety, so clinical study of this preparation as a myocardial perfusion imaging agent is worthwhile.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app